

# A John Rush

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/11603300/a-john-rush-publications-by-year.pdf>  
**Version:** 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

476 papers	51,049 citations	106 h-index	215 g-index
496 ext. papers	57,283 ext. citations	5.9 avg, IF	7.01 L-index

#	Paper	IF	Citations
476	Metabolomic and inflammatory signatures of symptom dimensions in major depression.. <i>Brain, Behavior, and Immunity</i> , <b>2022</b> , 102, 42-52	16.6	1
475	Clinical research challenges posed by difficult-to-treat depression.. <i>Psychological Medicine</i> , <b>2022</b> , 1-14	6.9	1
474	Psychometric and Clinical Evaluation of the Clinician (VQIDS-C) and Self-Report (VQIDS-SR) Versions of the Very Quick Inventory of Depressive Symptoms.. <i>Neuropsychiatric Disease and Treatment</i> , <b>2022</b> , 18, 289-302	3.1	0
473	Genomics-based identification of a potential causal role for acylcarnitine metabolism in depression.. <i>Journal of Affective Disorders</i> , <b>2022</b> , 307, 254-263	6.6	1
472	NeuroBlu, an electronic health record (EHR) trusted research environment (TRE) to support mental healthcare analytics with real-world data.. <i>BMJ Open</i> , <b>2022</b> , 12, e057227	3	1
471	Anterior cingulate cortex in individuals with depressive symptoms: A structural MRI study. <i>Psychiatry Research - Neuroimaging</i> , <b>2021</b> , 319, 111420	2.9	0
470	Indoxyl sulfate, a gut microbiome-derived uremic toxin, is associated with psychic anxiety and its functional magnetic resonance imaging-based neurologic signature. <i>Scientific Reports</i> , <b>2021</b> , 11, 21011	4.9	7
469	Psychometric Evaluation of the Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire in a General Youth Population. <i>Child Psychiatry and Human Development</i> , <b>2021</b> , 1	3.3	0
468	EEG biomarker informed prescription of antidepressants in MDD: a feasibility trial. <i>European Neuropsychopharmacology</i> , <b>2021</b> , 44, 14-22	1.2	5
467	Can the digital revolution improve care for mood disorders patients?. <i>Journal of Affective Disorders</i> , <b>2021</b> , 282, 1193-1194	6.6	1
466	Differential response to SSRI versus Placebo and distinct neural signatures among data-driven subgroups of patients with major depressive disorder. <i>Journal of Affective Disorders</i> , <b>2021</b> , 282, 602-610	6.6	0
465	Setting Measurement-Based Care in Motion: Practical Lessons in the Implementation and Integration of Measurement-Based Care in Psychiatry Clinical Practice. <i>Neuropsychiatric Disease and Treatment</i> , <b>2021</b> , 17, 1621-1631	3.1	3
464	Clinically meaningful changes on depressive symptom measures and patient-reported outcomes in patients with treatment-resistant depression. <i>Acta Psychiatrica Scandinavica</i> , <b>2021</b> , 143, 253-263	6.5	4
463	Bupropion and Naltrexone in Methamphetamine Use Disorder. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, 140-153	59.2	54
462	Alterations in acylcarnitines, amines, and lipids inform about the mechanism of action of citalopram/escitalopram in major depression. <i>Translational Psychiatry</i> , <b>2021</b> , 11, 153	8.6	16
461	Antidepressant side effects and their impact on treatment outcome in people with major depressive disorder: an iSPOT-D report. <i>Translational Psychiatry</i> , <b>2021</b> , 11, 417	8.6	4
460	Impact of childhood maltreatment on outcomes of antidepressant medication in chronic and/or recurrent depression. <i>Journal of Affective Disorders</i> , <b>2021</b> , 291, 39-45	6.6	1

459	Prediction of short-term antidepressant response using probabilistic graphical models with replication across multiple drugs and treatment settings. <i>Neuropsychopharmacology</i> , <b>2021</b> , 46, 1272-1282	8.7	4
458	The Adolescent Resilience Questionnaire: Validation of a Shortened Version in U.S. Youths. <i>Frontiers in Psychology</i> , <b>2020</b> , 11, 606373	3.4	1
457	Predicting future suicidal events in adolescents using the Concise Health Risk Tracking Self-Report (CHRT-SR). <i>Journal of Psychiatric Research</i> , <b>2020</b> , 126, 19-25	5.2	2
456	A prospective, multi-center randomized, controlled, blinded trial of vagus nerve stimulation for difficult to treat depression: A novel design for a novel treatment. <i>Contemporary Clinical Trials</i> , <b>2020</b> , 95, 106066	2.3	7
455	Positive and negative valence systems in major depression have distinct clinical features, response to antidepressants, and relationships with immunomarkers. <i>Depression and Anxiety</i> , <b>2020</b> , 37, 771-783	8.4	5
454	The effects of vagus nerve stimulation on the course and outcomes of patients with bipolar disorder in a treatment-resistant depressive episode: a 5-year prospective registry. <i>International Journal of Bipolar Disorders</i> , <b>2020</b> , 8, 13	5.4	9
453	Using the NIH Research, Condition and Disease Categorization Database for research advocacy: Schizophrenia research at NIMH as an example. <i>PLoS ONE</i> , <b>2020</b> , 15, e0241062	3.7	4
452	The Long and Winding Road of Vagus Nerve Stimulation: Challenges in Developing an Intervention for Difficult-to-Treat Mood Disorders. <i>Neuropsychiatric Disease and Treatment</i> , <b>2020</b> , 16, 3081-3093	3.1	2
451	Natural Language Processing-Based Quantification of the Mental State of Psychiatric Patients. <i>Computational Psychiatry</i> , <b>2020</b> , 4, 76	3.8	2
450	Acylcarnitine metabolomic profiles inform clinically-defined major depressive phenotypes. <i>Journal of Affective Disorders</i> , <b>2020</b> , 264, 90-97	6.6	16
449	Childhood maltreatment and impact on clinical features of major depression in adults. <i>Psychiatry Research</i> , <b>2020</b> , 293, 113412	9.9	6
448	Can psychological features predict antidepressant response to rTMS? A Discovery-Replication approach. <i>Psychological Medicine</i> , <b>2020</b> , 50, 264-272	6.9	11
447	Pilot Study of Metabolomic Clusters as State Markers of Major Depression and Outcomes to CBT Treatment. <i>Frontiers in Neuroscience</i> , <b>2019</b> , 13, 926	5.1	8
446	Gender-specific structural abnormalities in major depressive disorder revealed by voxel-based analysis. <i>NeuroImage: Clinical</i> , <b>2019</b> , 21, 101668	5.3	15
445	VitalSign: A Primary Care First (PCP-First) Model for Universal Screening and Measurement-Based Care for Depression. <i>Pharmaceuticals</i> , <b>2019</b> , 12,	5.2	17
444	Fatigue in Nondialysis Chronic Kidney Disease: Correlates and Association with Kidney Outcomes. <i>American Journal of Nephrology</i> , <b>2019</b> , 50, 37-47	4.6	14
443	Perception of Stigma and Its Associated Factors Among Patients With Major Depressive Disorder: A Multicenter Survey From an Asian Population. <i>Frontiers in Psychiatry</i> , <b>2019</b> , 10, 321	5	9
442	The symptom-specific efficacy of antidepressant medication vs. cognitive behavioral therapy in the treatment of depression: results from an individual patient data meta-analysis. <i>World Psychiatry</i> , <b>2019</b> , 18, 183-191	14.4	40

441	Pharmacogenomics-Driven Prediction of Antidepressant Treatment Outcomes: A Machine-Learning Approach With Multi-trial Replication. <i>Clinical Pharmacology and Therapeutics</i> , <b>2019</b> , 106, 855-865	6.1	40
440	Prediction of Acute-Phase Treatment Outcomes by Adding a Single-Item Measure of Activity Impairment to Symptom Measurement: Development and Validation of an Interactive Calculator from the STAR*D and CO-MED Trials. <i>International Journal of Neuropsychopharmacology</i> , <b>2019</b> , 22, 339-348	5.8	2
439	The assessment of resistance to antidepressant treatment: Rationale for the Antidepressant Treatment History Form: Short Form (ATHF-SF). <i>Journal of Psychiatric Research</i> , <b>2019</b> , 113, 125-136	5.2	25
438	Irritability and Its Clinical Utility in Major Depressive Disorder: Prediction of Individual-Level Acute-Phase Outcomes Using Early Changes in Irritability and Depression Severity. <i>American Journal of Psychiatry</i> , <b>2019</b> , 176, 358-366	11.9	19
437	Algorithms For Treatment of Major Depressive Disorder: Efficacy and Cost-Effectiveness. <i>Pharmacopsychiatry</i> , <b>2019</b> , 52, 117-125	2	14
436	A Structured Approach to Detecting and Treating Depression in Primary Care: VitalSign6 Project. <i>Annals of Family Medicine</i> , <b>2019</b> , 17, 326-335	2.9	16
435	Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients. <i>Translational Psychiatry</i> , <b>2019</b> , 9, 173	8.6	34
434	Toward a very brief quality of life enjoyment and Satisfaction Questionnaire. <i>Journal of Affective Disorders</i> , <b>2019</b> , 242, 87-95	6.6	7
433	Pharmacokinetic-Pharmacodynamic interaction associated with venlafaxine-XR remission in patients with major depressive disorder with history of citalopram / escitalopram treatment failure. <i>Journal of Affective Disorders</i> , <b>2019</b> , 246, 62-68	6.6	5
432	Measurement-based care using DSM-5 for opioid use disorder: can we make opioid medication treatment more effective?. <i>Addiction</i> , <b>2019</b> , 114, 1346-1353	4.6	24
431	The Concise Health Risk Tracking Self-Report (CHRT-SR) assessment of suicidality in depressed outpatients: A psychometric evaluation. <i>Depression and Anxiety</i> , <b>2019</b> , 36, 313-320	8.4	1
430	Clinical Implications of the STAR*D Trial. <i>Handbook of Experimental Pharmacology</i> , <b>2019</b> , 250, 51-99	3.2	6
429	Psychometric properties of the concise health risk tracking (CHRT) in adolescents with suicidality. <i>Journal of Affective Disorders</i> , <b>2018</b> , 235, 45-51	6.6	11
428	A psychometric evaluation of the Concise Health Risk Tracking Self-Report (CHRT-SR)- a measure of suicidality-in patients with stimulant use disorder. <i>Journal of Psychiatric Research</i> , <b>2018</b> , 102, 65-71	5.2	6
427	Screening for panic-related anxiety in emergency department patients with cardiopulmonary complaints: A comparison of two self-report instruments. <i>Psychiatry Research</i> , <b>2018</b> , 263, 7-14	9.9	5
426	Worsening Anxiety, Irritability, Insomnia, or Panic Predicts Poorer Antidepressant Treatment Outcomes: Clinical Utility and Validation of the Concise Associated Symptom Tracking (CAST) Scale. <i>International Journal of Neuropsychopharmacology</i> , <b>2018</b> , 21, 325-332	5.8	19
425	Speculations on the Future of Psychiatric Diagnosis. <i>Journal of Nervous and Mental Disease</i> , <b>2018</b> , 206, 481-487	1.8	11
424	A Novel Strategy to Identify Placebo Responders: Prediction Index of Clinical and Biological Markers in the EMBARC Trial. <i>Psychotherapy and Psychosomatics</i> , <b>2018</b> , 87, 285-295	9.4	28

423	Do baseline sub-threshold hypomanic symptoms affect acute-phase antidepressant outcome in outpatients with major depressive disorder? Preliminary findings from the randomized CO-MED trial. <i>Neuropsychopharmacology</i> , <b>2018</b> , 43, 2197-2203	8.7	8
422	A Clinician's Perspective on Biomarkers. <i>Focus (American Psychiatric Publishing)</i> , <b>2018</b> , 16, 124-134	1.1	9
421	Chronic Vagus Nerve Stimulation Significantly Improves Quality of Life in Treatment-Resistant Major Depression. <i>Journal of Clinical Psychiatry</i> , <b>2018</b> , 79,	4.6	31
420	Simultaneous rTMS and psychotherapy in major depressive disorder: Clinical outcomes and predictors from a large naturalistic study. <i>Brain Stimulation</i> , <b>2018</b> , 11, 337-345	5.1	64
419	When Discontinuing SSRI Antidepressants Is a Challenge: Management Tips. <i>American Journal of Psychiatry</i> , <b>2018</b> , 175, 1176-1184	11.9	21
418	Improving Depression Outcome by Patient-Centered Medical Management. <i>American Journal of Psychiatry</i> , <b>2018</b> , 175, 1187-1198	11.9	18
417	A Brief Interview to Detect Panic Attacks and Panic Disorder in Emergency Department Patients with Cardiopulmonary Complaints. <i>Journal of Psychiatric Practice</i> , <b>2018</b> , 24, 32-44	1.3	4
416	Mapping depression rating scale phenotypes onto research domain criteria (RDoC) to inform biological research in mood disorders. <i>Journal of Affective Disorders</i> , <b>2018</b> , 238, 1-7	6.6	17
415	Can C-reactive protein inform antidepressant medication selection in depressed outpatients? Findings from the CO-MED trial. <i>Psychoneuroendocrinology</i> , <b>2017</b> , 78, 105-113	5	118
414	Targeting treatments for depression: what can our patients tell us?. <i>Epidemiology and Psychiatric Sciences</i> , <b>2017</b> , 26, 37-39	5.1	3
413	Toward a very brief self-report to assess the core symptoms of depression (VQIDS-SR ). <i>Acta Psychiatrica Scandinavica</i> , <b>2017</b> , 135, 548-553	6.5	6
412	Personalizing antidepressant choice by sex, body mass index, and symptom profile: An iSPOT-D report. <i>Personalized Medicine in Psychiatry</i> , <b>2017</b> , 1-2, 65-73	1.1	15
411	Effect of Sertraline on Depressive Symptoms in Patients With Chronic Kidney Disease Without Dialysis Dependence: The CAST Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2017</b> , 318, 1876-1890	27.4	61
410	Daily activity level improvement with antidepressant medications predicts long-term clinical outcomes in outpatients with major depressive disorder. <i>Neuropsychiatric Disease and Treatment</i> , <b>2017</b> , 13, 803-813	3.1	15
409	Prediction of treatment outcomes to exercise in patients with nonremitted major depressive disorder. <i>Depression and Anxiety</i> , <b>2017</b> , 34, 1116-1122	8.4	21
408	Addressing the unmet needs of current antidepressants: does neuroscience help or hinder clinical psychopharmacology research?. <i>Expert Opinion on Pharmacotherapy</i> , <b>2017</b> , 18, 1417-1420	4	1
407	Data-driven longitudinal modeling and prediction of symptom dynamics in major depressive disorder: Integrating factor graphs and learning methods <b>2017</b> ,		7
406	Accurately identifying patients who are excellent candidates or unsuitable for a medication: a novel approach. <i>Neuropsychiatric Disease and Treatment</i> , <b>2017</b> , 13, 3001-3010	3.1	3

405	Early Improvement in Work Productivity Predicts Future Clinical Course in Depressed Outpatients: Findings From the CO-MED Trial. <i>American Journal of Psychiatry</i> , <b>2016</b> , 173, 1196-1204	11.9	33
404	A Brief Clinical Tool to Estimate Individual Patients Risk of Depressive Relapse Following Remission: Proof of Concept. <i>American Journal of Psychiatry</i> , <b>2016</b> , 173, 1140-1146	11.9	12
403	Early normalization of Quality of Life predicts later remission in depression: Findings from the CO-MED trial. <i>Journal of Affective Disorders</i> , <b>2016</b> , 206, 17-22	6.6	16
402	Estimating optimal shared-parameter dynamic regimens with application to a multistage depression clinical trial. <i>Biometrics</i> , <b>2016</b> , 72, 865-76	1.8	9
401	Divergent Outcomes in Cognitive-Behavioral Therapy and Pharmacotherapy for Adult Depression. <i>American Journal of Psychiatry</i> , <b>2016</b> , 173, 481-90	11.9	28
400	Clinical Experience With High-Dosage Pramipexole in Patients With Treatment-Resistant Depressive Episodes in Unipolar and Bipolar Depression. <i>American Journal of Psychiatry</i> , <b>2016</b> , 173, 107-111	11.9	45
399	Prediction of nonremission to antidepressant therapy using diffusion tensor imaging. <i>Journal of Clinical Psychiatry</i> , <b>2016</b> , 77, e436-43	4.6	21
398	A New Empirical Definition of Major Depressive Episode Recovery and Its Positive Impact on Future Course of Illness. <i>Journal of Clinical Psychiatry</i> , <b>2016</b> , 77, 1065-73	4.6	23
397	Toward precision medicine for depression: admitting ignorance and focusing on failures. <i>World Psychiatry</i> , <b>2016</b> , 15, 242-243	14.4	
396	Performance of depression rating scales in patients with chronic kidney disease: an item response theory-based analysis. <i>General Hospital Psychiatry</i> , <b>2016</b> , 42, 60-6	5.6	8
395	A cognitive-emotional biomarker for predicting remission with antidepressant medications: a report from the iSPOT-D trial. <i>Neuropsychopharmacology</i> , <b>2015</b> , 40, 1332-42	8.7	71
394	The Edinburgh Postnatal Depression Scale as a measure for antenatal dysphoria. <i>Journal of Reproductive and Infant Psychology</i> , <b>2015</b> , 33, 28-41	2.9	10
393	Depression Subtypes in Predicting Antidepressant Response: A Report From the iSPOT-D Trial. <i>American Journal of Psychiatry</i> , <b>2015</b> , 172, 743-50	11.9	106
392	Baseline Depression Severity as Moderator of Depression Outcomes Between Cognitive Behavioral Therapy vs Pharmacotherapy: An Individual Patient Data Meta-analysis. <i>JAMA Psychiatry</i> , <b>2015</b> , 72, 1102-9	14.5	117
391	Pre-treatment insomnia as a predictor of single and combination antidepressant outcomes: a CO-MED report. <i>Journal of Affective Disorders</i> , <b>2015</b> , 174, 157-64	6.6	16
390	Toward an online cognitive and emotional battery to predict treatment remission in depression. <i>Neuropsychiatric Disease and Treatment</i> , <b>2015</b> , 11, 517-31	3.1	13
389	Impairment and distress patterns distinguishing the melancholic depression subtype: an iSPOT-D report. <i>Journal of Affective Disorders</i> , <b>2015</b> , 174, 493-502	6.6	11
388	Magnetic Resonance Imaging Measures of Brain Structure to Predict Antidepressant Treatment Outcome in Major Depressive Disorder. <i>EBioMedicine</i> , <b>2015</b> , 2, 37-45	8.8	41



387	The international Study to Predict Optimized Treatment in Depression (iSPOT-D): outcomes from the acute phase of antidepressant treatment. <i>Journal of Psychiatric Research</i> , <b>2015</b> , 61, 1-12	5.2	90
386	Narrowing the gaps between what we know and what we do in psychiatry. <i>Journal of Clinical Psychiatry</i> , <b>2015</b> , 76, 1366-72	4.6	6
385	Distinguishing functional from syndromal recovery: implications for clinical care and research. <i>Journal of Clinical Psychiatry</i> , <b>2015</b> , 76, e832-4	4.6	13
384	Medical test development and implementation: a multistep journey. <i>Journal of Clinical Psychiatry</i> , <b>2015</b> , 76, e220-1	4.6	1
383	Variable and threshold selection to control predictive accuracy in logistic regression. <i>Journal of the Royal Statistical Society Series C: Applied Statistics</i> , <b>2014</b> , 63, 657-672	1.5	3
382	A randomized, double-blind, placebo-controlled trial of quetiapine in patients with bipolar disorder, mixed or depressed phase, and alcohol dependence. <i>Alcoholism: Clinical and Experimental Research</i> , <b>2014</b> , 38, 2113-8	3.7	28
381	Association of depressive symptoms with hippocampal volume in 1936 adults. <i>Neuropsychopharmacology</i> , <b>2014</b> , 39, 770-9	8.7	45
380	Ketamine for Treatment-Resistant Depression: Ready or Not for Clinical Use?. <i>Focus (American Psychiatric Publishing)</i> , <b>2014</b> , 12, 244-245	1.1	
379	Adherence to antidepressant combinations and monotherapy for major depressive disorder: a CO-MED report of measurement-based care. <i>Journal of Psychiatric Practice</i> , <b>2014</b> , 20, 118-32	1.3	19
378	Brief, unidimensional melancholia rating scales are highly sensitive to the effect of citalopram and may have biological validity: implications for the research domain criteria (RDoC). <i>Journal of Affective Disorders</i> , <b>2014</b> , 163, 18-24	6.6	30
377	Retention and attrition among African Americans in the STAR*D study: what causes research volunteers to stay or stray?. <i>Depression and Anxiety</i> , <b>2013</b> , 30, 1137-44	8.4	13
376	Rationale and design of the Chronic Kidney Disease Antidepressant Sertraline Trial (CAST). <i>Contemporary Clinical Trials</i> , <b>2013</b> , 34, 136-44	2.3	22
375	Fluoxetine increases suicide ideation less than placebo during treatment of adults with minor depressive disorder. <i>Journal of Psychiatric Research</i> , <b>2013</b> , 47, 1199-203	5.2	9
374	The clinical relevance of self-reported premenstrual worsening of depressive symptoms in the management of depressed outpatients: a STAR*D report. <i>Journal of Women's Health</i> , <b>2013</b> , 22, 219-29	3	20
373	Do menopausal status and use of hormone therapy affect antidepressant treatment response? Findings from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study. <i>Journal of Women's Health</i> , <b>2013</b> , 22, 121-31	3	30
372	Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies. <i>American Journal of Psychiatry</i> , <b>2013</b> , 170, 207-17	11.9	181
371	Increase in work productivity of depressed individuals with improvement in depressive symptom severity. <i>American Journal of Psychiatry</i> , <b>2013</b> , 170, 633-41	11.9	84
370	Clinical features of depression in Asia: results of a large prospective, cross-sectional study. <i>Asia-Pacific Psychiatry</i> , <b>2013</b> , 5, 259-67	3.2	19

369	Clinical and sociodemographic characteristics associated with suicidal ideation in depressed outpatients. <i>Canadian Journal of Psychiatry</i> , <b>2013</b> , 58, 113-22	4.8	25
368	A patient-level meta-analysis of studies evaluating vagus nerve stimulation therapy for treatment-resistant depression. <i>Medical Devices: Evidence and Research</i> , <b>2013</b> , 6, 17-35	1.5	46
367	Combining Medications to Enhance Depression Outcomes (CO-MED): Acute and Long-Term Outcomes of a Single-Blind Randomized Study. <i>Focus (American Psychiatric Publishing)</i> , <b>2012</b> , 10, 492-505 <sup>1.1</sup>	1.1	1
366	What Did STAR*D Teach Us? Results From a Large-Scale, Practical, Clinical Trial for Patients With Depression. <i>Focus (American Psychiatric Publishing)</i> , <b>2012</b> , 10, 510-517	1.1	
365	Baseline depression severity as a predictor of single and combination antidepressant treatment outcome: results from the CO-MED trial. <i>European Neuropsychopharmacology</i> , <b>2012</b> , 22, 183-99	1.2	48
364	Estimating Individualized Treatment Rules Using Outcome Weighted Learning. <i>Journal of the American Statistical Association</i> , <b>2012</b> , 107, 1106-1118	2.8	335
363	What are the clinical implications of new onset or worsening anxiety during the first two weeks of SSRI treatment for depression?. <i>Depression and Anxiety</i> , <b>2012</b> , 29, 94-101	8.4	20
362	Effect of concurrent substance use disorder on the effectiveness of single and combination antidepressant medications for the treatment of major depression: an exploratory analysis of a single-blind randomized trial. <i>Depression and Anxiety</i> , <b>2012</b> , 29, 111-22	8.4	13
361	Effects of heart disease on depression treatment: results from the COMED study. <i>General Hospital Psychiatry</i> , <b>2012</b> , 34, 24-34	5.6	4
360	Depression treatment in patients with general medical conditions: results from the CO-MED trial. <i>Annals of Family Medicine</i> , <b>2012</b> , 10, 23-33	2.9	28
359	Common genetic variation in the indoleamine-2,3-dioxygenase genes and antidepressant treatment outcome in major depressive disorder. <i>Journal of Psychopharmacology</i> , <b>2012</b> , 26, 360-7	4.6	32
358	Correlates and outcomes of depressed out-patients with greater and fewer anxious symptoms: a CO-MED report. <i>International Journal of Neuropsychopharmacology</i> , <b>2012</b> , 15, 1387-99	5.8	18
357	The impact of chronic depression on acute and long-term outcomes in a randomized trial comparing selective serotonin reuptake inhibitor monotherapy versus each of 2 different antidepressant medication combinations. <i>Journal of Clinical Psychiatry</i> , <b>2012</b> , 73, 967-76	4.6	23
356	The effectiveness of antidepressant monotherapy in a naturalistic outpatient setting. <i>primary care companion for CNS disorders, The</i> , <b>2012</b> , 14,	1.2	4
355	The relationship between adverse events during selective serotonin reuptake inhibitor treatment for major depressive disorder and nonremission in the suicide assessment methodology study. <i>Journal of Clinical Psychopharmacology</i> , <b>2011</b> , 31, 31-8	1.7	13
354	Changes in depressive symptoms and social functioning in the sequenced treatment alternatives to relieve depression study. <i>Journal of Nervous and Mental Disease</i> , <b>2011</b> , 199, 807-10	1.8	15
353	International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: rationale and protocol. <i>Trials</i> , <b>2011</b> , 12, 4	2.8	126
352	Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: a CO-MED report. <i>Journal of Affective Disorders</i> , <b>2011</b> , 133, 467-76	6.6	42



351	Assessing anxious features in depressed outpatients. <i>International Journal of Methods in Psychiatric Research</i> , <b>2011</b> , 20, e69-82	4.3	15
350	Star-D: lessons learned and future implications. <i>Depression and Anxiety</i> , <b>2011</b> , 28, 521-4	8.4	25
349	Association between bipolar spectrum features and treatment outcomes in outpatients with major depressive disorder. <i>Archives of General Psychiatry</i> , <b>2011</b> , 68, 351-60		99
348	Children of depressed mothers 1 year after remission of maternal depression: findings from the STAR*D-Child study. <i>American Journal of Psychiatry</i> , <b>2011</b> , 168, 593-602	11.9	124
347	Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. <i>American Journal of Psychiatry</i> , <b>2011</b> , 168, 689-701	11.9	266
346	Effects of race and ethnicity on depression treatment outcomes: the CO-MED trial. <i>Psychiatric Services</i> , <b>2011</b> , 62, 1167-79	3.3	25
345	Measurement-based care in psychiatric practice: a policy framework for implementation. <i>Journal of Clinical Psychiatry</i> , <b>2011</b> , 72, 1136-43	4.6	101
344	Concise Health Risk Tracking scale: a brief self-report and clinician rating of suicidal risk. <i>Journal of Clinical Psychiatry</i> , <b>2011</b> , 72, 757-64	4.6	81
343	Concise Associated Symptoms Tracking scale: a brief self-report and clinician rating of symptoms associated with suicidality. <i>Journal of Clinical Psychiatry</i> , <b>2011</b> , 72, 765-74	4.6	42
342	Association between major depressive episodes in patients with chronic kidney disease and initiation of dialysis, hospitalization, or death. <i>JAMA - Journal of the American Medical Association</i> , <b>2010</b> , 303, 1946-53	27.4	143
341	Combining antidepressant medications: a good idea?. <i>American Journal of Psychiatry</i> , <b>2010</b> , 167, 241-3	11.9	22
340	Prevalence of incompletely penetrant Huntington's disease alleles among individuals with major depressive disorder. <i>American Journal of Psychiatry</i> , <b>2010</b> , 167, 574-9	11.9	39
339	Association of polymorphisms in genes regulating the corticotropin-releasing factor system with antidepressant treatment response. <i>Archives of General Psychiatry</i> , <b>2010</b> , 67, 369-79		96
338	Cross-disorder genomewide analysis of schizophrenia, bipolar disorder, and depression. <i>American Journal of Psychiatry</i> , <b>2010</b> , 167, 1254-63	11.9	157
337	Genome-wide association study of suicide attempts in mood disorder patients. <i>American Journal of Psychiatry</i> , <b>2010</b> , 167, 1499-507	11.9	113
336	Does comorbid substance use disorder impair recovery from major depression with SSRI treatment? An analysis of the STAR*D level one treatment outcomes. <i>Drug and Alcohol Dependence</i> , <b>2010</b> , 107, 161-70	4.9	59
335	Do atypical features affect outcome in depressed outpatients treated with citalopram?. <i>International Journal of Neuropsychopharmacology</i> , <b>2010</b> , 13, 15-30	5.8	41
334	Early adverse events and attrition in selective serotonin reuptake inhibitor treatment: a suicide assessment methodology study report. <i>Journal of Clinical Psychopharmacology</i> , <b>2010</b> , 30, 259-66	1.7	17

333	The influence of menopause status and postmenopausal use of hormone therapy on presentation of major depression in women. <i>Menopause</i> , <b>2010</b> , 17, 828-39	2.5	43
332	The quick inventory of depressive symptomatology (clinician and self-report versions) in patients with bipolar disorder. <i>CNS Spectrums</i> , <b>2010</b> , 15, 367-73	1.8	19
331	Evaluation of the Effects of Severe Depression on Global Cognitive Function and Memory. <i>CNS Spectrums</i> , <b>2010</b> , 15, 304-13	1.8	22
330	Insomnia in patients with depression: a STAR*D report. <i>CNS Spectrums</i> , <b>2010</b> , 15, 394-404	1.8	102
329	A Comparison of the QIDS-C16, QIDS-SR16, and the MADRS in an Adult Outpatient Clinical Sample. <i>CNS Spectrums</i> , <b>2010</b> , 15, 458-68	1.8	20
328	The impact of diabetes on depression treatment outcomes. <i>General Hospital Psychiatry</i> , <b>2010</b> , 32, 33-41	5.6	20
327	Psychometric properties of the Quick Inventory of Depressive Symptomatology in adolescents. <i>International Journal of Methods in Psychiatric Research</i> , <b>2010</b> , 19, 185-94	4.3	75
326	Recursive subsetting to identify patients in the STAR*D: a method to enhance the accuracy of early prediction of treatment outcome and to inform personalized care. <i>Journal of Clinical Psychiatry</i> , <b>2010</b> , 71, 1502-8	4.6	36
325	What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. <i>Psychiatric Services</i> , <b>2009</b> , 60, 1439-45	3.3	368
324	Effectiveness Study of Venlafaxine-XR Combined with Aripiprazole for Chronic or Recurrent Major Depressive Disorder. <i>Australian and New Zealand Journal of Psychiatry</i> , <b>2009</b> , 43, 956-967	2.6	8
323	A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. <i>Archives of General Psychiatry</i> , <b>2009</b> , 66, 966-975		259
322	Identifying risk for attrition during treatment for depression. <i>Psychotherapy and Psychosomatics</i> , <b>2009</b> , 78, 372-9	9.4	20
321	Cognitive Therapy Augmentation versus CT Switch Treatment: A STAR*D Report. <i>International Journal of Cognitive Therapy</i> , <b>2009</b> , 2, 66-87	1.4	1
320	Can phase III trial results of antidepressant medications be generalized to clinical practice? A STAR*D report. <i>American Journal of Psychiatry</i> , <b>2009</b> , 166, 599-607	11.9	171
319	Pharmacogenetics Studies in STAR*D: Strengths, Limitations, and Results. <i>Psychiatric Services</i> , <b>2009</b> , 60, 1446-1457	3.3	58
318	Genetic and clinical predictors of sexual dysfunction in citalopram-treated depressed patients. <i>Neuropsychopharmacology</i> , <b>2009</b> , 34, 1819-28	8.7	78
317	What predicts attrition in second step medication treatments for depression?: a STAR*D Report. <i>International Journal of Neuropsychopharmacology</i> , <b>2009</b> , 12, 459-73	5.8	58
316	On the psychometric validity of the domains of the PDSQ: an illustration of the bi-factor item response theory model. <i>Journal of Psychiatric Research</i> , <b>2009</b> , 43, 401-10	5.2	39

315	Sex differences in response to citalopram: a STAR*D report. <i>Journal of Psychiatric Research</i> , <b>2009</b> , 43, 503-11	5.2	123
314	Clinical correlates of the worsening or emergence of suicidal ideation during SSRI treatment of depression: an examination of citalopram in the STAR*D study. <i>Journal of Affective Disorders</i> , <b>2009</b> , 117, 63-73	6.6	73
313	Validation of depression screening scales in patients with CKD. <i>American Journal of Kidney Diseases</i> , <b>2009</b> , 54, 433-9	7.4	87
312	Prevalence of major depressive episode in CKD. <i>American Journal of Kidney Diseases</i> , <b>2009</b> , 54, 424-32	7.4	132
311	Income and attrition in the treatment of depression: a STAR*D report. <i>Depression and Anxiety</i> , <b>2009</b> , 26, 622-33	8.4	39
310	Diurnal mood variation in outpatients with major depressive disorder. <i>Depression and Anxiety</i> , <b>2009</b> , 26, 851-63	8.4	18
309	Sociodemographic, clinical, and treatment characteristics associated with worsened depression during treatment with citalopram: results of the NIMH STAR(*)D trial. <i>Depression and Anxiety</i> , <b>2009</b> , 26, 612-21	8.4	25
308	A psychometric evaluation of the clinician-rated Quick Inventory of Depressive Symptomatology (QIDS-C16) in patients with bipolar disorder. <i>International Journal of Methods in Psychiatric Research</i> , <b>2009</b> , 18, 138-46	4.3	16
307	Release bias in accessing medical records in clinical trials: a STAR*D report. <i>International Journal of Methods in Psychiatric Research</i> , <b>2009</b> , 18, 147-58	4.3	1
306	Irritability is associated with anxiety and greater severity, but not bipolar spectrum features, in major depressive disorder. <i>Acta Psychiatrica Scandinavica</i> , <b>2009</b> , 119, 282-9	6.5	61
305	A randomized, double-blind, placebo-controlled pilot study of naltrexone in outpatients with bipolar disorder and alcohol dependence. <i>Alcoholism: Clinical and Experimental Research</i> , <b>2009</b> , 33, 1863-9	3.7	76
304	Concurrent anxiety and substance use disorders among outpatients with major depression: clinical features and effect on treatment outcome. <i>Drug and Alcohol Dependence</i> , <b>2009</b> , 99, 248-60	4.9	109
303	Clinical issues in considering vagus nerve stimulation for treatment-resistant depression. <i>Experimental Neurology</i> , <b>2009</b> , 219, 36-43	5.7	41
302	STAR*D: revising conventional wisdom. <i>CNS Drugs</i> , <b>2009</b> , 23, 627-47	6.7	172
301	The role of efficacy and effectiveness trials. <i>World Psychiatry</i> , <b>2009</b> , 8, 34-5	14.4	5
300	The impact of nonclinical factors on care use for patients with depression: a STAR*D report. <i>CNS Neuroscience and Therapeutics</i> , <b>2009</b> , 15, 320-32	6.8	9
299	Predictors of attrition during one year of depression treatment: a roadmap to personalized intervention. <i>Journal of Psychiatric Practice</i> , <b>2009</b> , 15, 113-24	1.3	22
298	Measuring use and cost of care for patients with mood disorders: the utilization and cost inventory. <i>Medical Care</i> , <b>2009</b> , 47, 184-90	3.1	11

297	Screening for major depression in private practice. <i>Journal of Psychiatric Practice</i> , <b>2009</b> , 15, 87-94	1.3	18
296	Genome-wide association study of suicidal ideation emerging during citalopram treatment of depressed outpatients. <i>Pharmacogenetics and Genomics</i> , <b>2009</b> , 19, 666-74	1.9	80
295	Factors associated with concomitant psychotropic drug use in the treatment of major depression: a STAR*D Report. <i>CNS Spectrums</i> , <b>2009</b> , 14, 487-98	1.8	8
294	Pharmacogenetics studies in STAR*D: strengths, limitations, and results. <i>Psychiatric Services</i> , <b>2009</b> , 60, 1446-57	3.3	41
293	Do depressed patients with diabetes experience more side effects when treated with Citalopram Than their counterparts without diabetes? a STAR*D study. <i>Primary Care Companion To the Journal of Clinical Psychiatry</i> , <b>2009</b> , 11, 186-96		
292	Voice response system to measure healthcare costs: a STAR*D report. <i>American Journal of Managed Care</i> , <b>2009</b> , 15, 153-62	2.1	3
291	A comparison of baseline sociodemographic and clinical characteristics between major depressive disorder patients with and without diabetes: a STAR*D report. <i>Journal of Affective Disorders</i> , <b>2008</b> , 108, 113-20	6.6	13
290	Family history of completed suicide and characteristics of major depressive disorder: a STAR*D (sequenced treatment alternatives to relieve depression) study. <i>Journal of Affective Disorders</i> , <b>2008</b> , 108, 129-34	6.6	12
289	The Brief Adherence Rating Scale (BARS) validated against electronic monitoring in assessing the antipsychotic medication adherence of outpatients with schizophrenia and schizoaffective disorder. <i>Schizophrenia Research</i> , <b>2008</b> , 100, 60-9	3.6	134
288	The FKBP5-gene in depression and treatment response--an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort. <i>Biological Psychiatry</i> , <b>2008</b> , 63, 1103-10	7.9	218
287	Sexual functioning associated with quetiapine switch vs. risperidone continuation in outpatients with schizophrenia or schizoaffective disorder: a randomized double-blind pilot trial. <i>Psychiatry Research</i> , <b>2008</b> , 159, 115-20	9.9	22
286	Electronic monitoring of antipsychotic medication adherence in outpatients with schizophrenia or schizoaffective disorder: an empirical evaluation of its reliability and predictive validity. <i>Psychiatry Research</i> , <b>2008</b> , 157, 259-63	9.9	31
285	Daily process methodology for measuring earlier antidepressant response. <i>Contemporary Clinical Trials</i> , <b>2008</b> , 29, 867-77	2.3	21
284	Sex differences in depression symptoms in treatment-seeking adults: confirmatory analyses from the Sequenced Treatment Alternatives to Relieve Depression study. <i>Comprehensive Psychiatry</i> , <b>2008</b> , 49, 238-46	7.3	156
283	The Quick Inventory of Depressive Symptomatology-Self-report: a psychometric evaluation in patients with asthma and major depressive disorder. <i>Annals of Allergy, Asthma and Immunology</i> , <b>2008</b> , 100, 433-8	3.2	23
282	Treatment outcomes for older depressed patients with earlier versus late onset of first depressive episode: a Sequenced Treatment Alternatives to Relieve Depression (STAR*D) report. <i>American Journal of Geriatric Psychiatry</i> , <b>2008</b> , 16, 58-64	6.5	32
281	Remission of maternal depression: relations to family functioning and youth internalizing and externalizing symptoms. <i>Journal of Clinical Child and Adolescent Psychology</i> , <b>2008</b> , 37, 714-24	5.4	47
280	Antecedentes familiares de suicidio consumado y características del trastorno depresivo mayor: estudio STAR*D (sequenced treatment alternatives to relieve depression). <i>Psiquiatria Biologica</i> , <b>2008</b> , 15, 195-201	0.2	

279	Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features. <i>Archives of General Psychiatry</i> , <b>2008</b> , 65, 870-80		125
278	Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. <i>American Journal of Psychiatry</i> , <b>2008</b> , 165, 342-51	11.9	594
277	Pharmacogenetic analysis of genes implicated in rodent models of antidepressant response: association of TREK1 and treatment resistance in the STAR(*)D study. <i>Neuropsychopharmacology</i> , <b>2008</b> , 33, 2810-9	8.7	89
276	Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report. <i>Focus (American Psychiatric Publishing)</i> , <b>2008</b> , 6, 128-142	1.1	9
275	Fluoxetine versus placebo in preventing relapse of major depression in children and adolescents. <i>American Journal of Psychiatry</i> , <b>2008</b> , 165, 459-67	11.9	132
274	Children of depressed mothers 1 year after the initiation of maternal treatment: findings from the STAR*D-Child Study. <i>American Journal of Psychiatry</i> , <b>2008</b> , 165, 1136-47	11.9	146
273	Developing the evidence for evidence-based practice. <i>Cmaj</i> , <b>2008</b> , 178, 1313-5	3.5	4
272	Folate and unipolar depression. <i>Journal of Alternative and Complementary Medicine</i> , <b>2008</b> , 14, 277-85	2.4	44
271	Cognitive Therapy Versus Medication in Augmentation and Switch Strategies as Second-Step Treatments: A STAR*D Report. <i>Focus (American Psychiatric Publishing)</i> , <b>2008</b> , 6, 104-119	1.1	
270	Faster remission of chronic depression with combined psychotherapy and medication than with each therapy alone. <i>Journal of Consulting and Clinical Psychology</i> , <b>2008</b> , 76, 459-67	6.5	44
269	Fluoxetine Versus Placebo in Preventing Relapse of Major Depression in Children and Adolescents. <i>Focus (American Psychiatric Publishing)</i> , <b>2008</b> , 6, 348-357	1.1	1
268	Improving the prediction of treatment response in depression: integration of clinical, cognitive, psychophysiological, neuroimaging, and genetic measures. <i>CNS Spectrums</i> , <b>2008</b> , 13, 1066-86; quiz 1087-8	1.8	125
267	Dr. Rush Replies. <i>American Journal of Psychiatry</i> , <b>2008</b> , 165, 133-134	11.9	2
266	Depression outcomes of Spanish- and english-speaking Hispanic outpatients in STAR*D. <i>Psychiatric Services</i> , <b>2008</b> , 59, 1273-84	3.3	26
265	Genetic Markers of Suicidal Ideation Emerging During Citalopram Treatment of Major Depression. <i>Focus (American Psychiatric Publishing)</i> , <b>2008</b> , 6, 69-79	1.1	
264	An open pilot study of the combination of escitalopram and bupropion-SR for outpatients with major depressive disorder. <i>Journal of Psychiatric Practice</i> , <b>2008</b> , 14, 271-80	1.3	34
263	Course and Severity of Maternal Depression: Associations with Family Functioning and Child Adjustment. <i>Journal of Youth and Adolescence</i> , <b>2008</b> , 37, 906-916	4.5	68
262	Primary versus specialty care outcomes for depressed outpatients managed with measurement-based care: results from STAR*D. <i>Journal of General Internal Medicine</i> , <b>2008</b> , 23, 551-60	4	74

261	Symptom features of postpartum depression: are they distinct?. <i>Depression and Anxiety</i> , <b>2008</b> , 25, 20-6	8.4	81
260	Clinically Relevant Findings from STAR*D. <i>Psychiatric Annals</i> , <b>2008</b> , 38,	0.5	11
259	The efficacy of acute electroconvulsive therapy in atypical depression. <i>Journal of Clinical Psychiatry</i> , <b>2008</b> , 69, 406-11	4.6	28
258	Does the duration of index episode affect the treatment outcome of major depressive disorder? A STAR*D report. <i>Journal of Clinical Psychiatry</i> , <b>2008</b> , 69, 1246-56	4.6	31
257	Response to a selective serotonin reuptake inhibitor (citalopram) in major depressive disorder with melancholic features: a STAR*D report. <i>Journal of Clinical Psychiatry</i> , <b>2008</b> , 69, 1847-55	4.6	80
256	A psychometric evaluation of the CDRS and MADRS in assessing depressive symptoms in children. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , <b>2007</b> , 46, 1204-1212	7.2	34
255	Sertraline as a first-line treatment for cholestatic pruritus. <i>Hepatology</i> , <b>2007</b> , 45, 666-74	11.2	207
254	Clinical differences among depressed patients with and without a history of suicide attempts: findings from the STAR*D trial. <i>Journal of Affective Disorders</i> , <b>2007</b> , 97, 77-84	6.6	59
253	Dropouts versus completers among chronically depressed outpatients. <i>Journal of Affective Disorders</i> , <b>2007</b> , 97, 197-202	6.6	112
252	Comorbid disorders in patients with bipolar disorder and concomitant substance dependence. <i>Journal of Affective Disorders</i> , <b>2007</b> , 102, 281-7	6.6	49
251	Assessing the preventive effects of cognitive therapy following relief of depression: A methodological innovation. <i>Journal of Affective Disorders</i> , <b>2007</b> , 104, 251-61	6.6	13
250	Influences of hormone-based contraception on depressive symptoms in premenopausal women with major depression. <i>Psychoneuroendocrinology</i> , <b>2007</b> , 32, 843-53	5	61
249	Family history of mood disorder and characteristics of major depressive disorder: a STAR*D (sequenced treatment alternatives to relieve depression) study. <i>Journal of Psychiatric Research</i> , <b>2007</b> , 41, 214-21	5.2	49
248	Clinical vs. self-report versions of the quick inventory of depressive symptomatology in a public sector sample. <i>Journal of Psychiatric Research</i> , <b>2007</b> , 41, 239-46	5.2	40
247	Electronic source materials in clinical research: acceptability and validity of symptom self-rating in major depressive disorder. <i>Journal of Psychiatric Research</i> , <b>2007</b> , 41, 737-43	5.2	18
246	Remission of maternal depression and child symptoms among single mothers: a STAR*D-Child report. <i>Social Psychiatry and Psychiatric Epidemiology</i> , <b>2007</b> , 42, 962-71	4.5	26
245	The STAR*D Project results: a comprehensive review of findings. <i>Current Psychiatry Reports</i> , <b>2007</b> , 9, 449-59	9.1	443
244	Maximizing the adequacy of medication treatment in controlled trials and clinical practice: STAR(*)D measurement-based care. <i>Neuropsychopharmacology</i> , <b>2007</b> , 32, 2479-89	8.7	106



243	Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report. <i>American Journal of Psychiatry</i> , <b>2007</b> , 164, 739-52	11.9	246
242	Genetic markers of suicidal ideation emerging during citalopram treatment of major depression. <i>American Journal of Psychiatry</i> , <b>2007</b> , 164, 1530-8	11.9	171
241	Association between treatment-emergent suicidal ideation with citalopram and polymorphisms near cyclic adenosine monophosphate response element binding protein in the STAR*D study. <i>Archives of General Psychiatry</i> , <b>2007</b> , 64, 689-97		106
240	The relationship between serum prolactin level and sexual functioning among male outpatients with schizophrenia or schizoaffective disorder: a randomized double-blind trial of risperidone vs. quetiapine. <i>Journal of Sex and Marital Therapy</i> , <b>2007</b> , 33, 203-16	2.7	39
239	Insured and non-insured depressed outpatients: how do they compare?. <i>Annals of Clinical Psychiatry</i> , <b>2007</b> , 19, 73-82	1.4	4
238	Acceptability of second-step treatments to depressed outpatients: a STAR*D report. <i>American Journal of Psychiatry</i> , <b>2007</b> , 164, 753-60	11.9	56
237	Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort. <i>American Journal of Psychiatry</i> , <b>2007</b> , 164, 1181-8	11.9	169
236	Predictors of attrition during initial (citalopram) treatment for depression: a STAR*D report. <i>American Journal of Psychiatry</i> , <b>2007</b> , 164, 1189-97	11.9	106
235	Effect of age at onset on the course of major depressive disorder. <i>American Journal of Psychiatry</i> , <b>2007</b> , 164, 1539-46	11.9	295
234	Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. <i>Archives of General Psychiatry</i> , <b>2007</b> , 64, 783-92		182
233	Major depression symptoms in primary care and psychiatric care settings: a cross-sectional analysis. <i>Annals of Family Medicine</i> , <b>2007</b> , 5, 126-34	2.9	79
232	DSM melancholic features are unreliable predictors of ECT response: a CORE publication. <i>Journal of ECT</i> , <b>2007</b> , 23, 139-46	2	39
231	Validity of electronically monitored medication adherence and conventional adherence measures in schizophrenia. <i>Psychiatric Services</i> , <b>2007</b> , 58, 844-7	3.3	91
230	Ethnicity/race and outcome in the treatment of depression: results from STAR*D. <i>Medical Care</i> , <b>2007</b> , 45, 1043-51	3.1	43
229	Comparison of quality of life measures in a depressed population. <i>Journal of Nervous and Mental Disease</i> , <b>2007</b> , 195, 219-25	1.8	27
228	STAR*D: what have we learned?. <i>American Journal of Psychiatry</i> , <b>2007</b> , 164, 201-4	11.9	250
227	Treatment with low doses of tranylcypromine resulted in a disappointing remission rate. <i>American Journal of Psychiatry</i> , <b>2007</b> , 164, 524; author reply 524	11.9	2
226	Durability of antidepressant response to vagus nerve stimulation (VNS). <i>International Journal of Neuropsychopharmacology</i> , <b>2007</b> , 10, 817-26	5.8	75

225	Bupropion in the treatment of outpatients with asthma and major depressive disorder. <i>International Journal of Psychiatry in Medicine</i> , <b>2007</b> , 37, 23-8	1	27
224	Constructing evidence-based treatment strategies using methods from computer science. <i>Drug and Alcohol Dependence</i> , <b>2007</b> , 88 Suppl 2, S52-60	4.9	33
223	Pain in depression: STAR*D study findings. <i>Journal of Psychosomatic Research</i> , <b>2007</b> , 63, 113-22	4.1	64
222	Major depressive disorder and comorbid cardiac disease: is there a depressive subtype with greater cardiovascular morbidity? Results from the STAR*D study. <i>Psychosomatics</i> , <b>2007</b> , 48, 418-25	2.6	24
221	Diurnal Mood Variation in Outpatients With Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , <b>2007</b> , 68, 1339-1347	4.6	29
220	A pilot study of an electronic, adolescent version of the quick inventory of depressive symptomatology. <i>Journal of Clinical Psychiatry</i> , <b>2007</b> , 68, 1436-40	4.6	18
219	Are depressed outpatients with and without a family history of substance use disorder different? A baseline analysis of the STAR*D cohort. <i>Journal of Clinical Psychiatry</i> , <b>2007</b> , 68, 1931-8	4.6	10
218	Clinical features of depression in outpatients with and without co-occurring general medical conditions in STAR*D: confirmatory analysis. <i>Primary Care Companion To the Journal of Clinical Psychiatry</i> , <b>2007</b> , 9, 7-15		44
217	Diurnal mood variation in outpatients with major depressive disorder: implications for DSM-V from an analysis of the Sequenced Treatment Alternatives to Relieve Depression Study data. <i>Journal of Clinical Psychiatry</i> , <b>2007</b> , 68, 1339-47	4.6	12
216	Making clinicians lives easier: guidance on use of the QIDS self-report in place of the MADRS. <i>Journal of Affective Disorders</i> , <b>2006</b> , 95, 115-8	6.6	27
215	Presenting characteristics of depressed outpatients as a function of recurrence: preliminary findings from the STAR*D clinical trial. <i>Journal of Psychiatric Research</i> , <b>2006</b> , 40, 59-69	5.2	78
214	Naltrexone in patients with bipolar disorder and alcohol dependence. <i>Depression and Anxiety</i> , <b>2006</b> , 23, 492-5	8.4	37
213	Remissions in maternal depression and child psychopathology: a STAR*D-child report. <i>JAMA - Journal of the American Medical Association</i> , <b>2006</b> , 295, 1389-98	27.4	442
212	A Comparison of Mirtazapine and Nortriptyline Following Two Consecutive Failed Medication Treatments for Depressed Outpatients: A STAR*D Report. <i>American Journal of Psychiatry</i> , <b>2006</b> , 163, 1161-1172	11.9	203
211	Report by the ACNP Task Force on response and remission in major depressive disorder. <i>Neuropsychopharmacology</i> , <b>2006</b> , 31, 1841-53	8.7	469
210	An empirical analysis of cost outcomes of the Texas Medication Algorithm Project. <i>Psychiatric Services</i> , <b>2006</b> , 57, 648-59	3.3	16
209	Clinical and demographic factors associated with DSM-IV melancholic depression. <i>Annals of Clinical Psychiatry</i> , <b>2006</b> , 18, 91-8	1.4	86
208	Current status of augmentation and combination treatments for major depressive disorder: a literature review and a proposal for a novel approach to improve practice. <i>Psychotherapy and Psychosomatics</i> , <b>2006</b> , 75, 139-53	9.4	118

207	A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. <i>American Journal of Psychiatry</i> , <b>2006</b> , 163, 1519-30; quiz 1665	11.9	380
206	Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. <i>American Journal of Psychiatry</i> , <b>2006</b> , 163, 28-40	11.9	2607
205	Medication augmentation after the failure of SSRIs for depression. <i>New England Journal of Medicine</i> , <b>2006</b> , 354, 1243-52	59.2	748
204	Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. <i>American Journal of Psychiatry</i> , <b>2006</b> , 163, 1905-17	11.9	3098
203	Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. <i>New England Journal of Medicine</i> , <b>2006</b> , 354, 1231-42	59.2	778
202	Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. <i>American Journal of Human Genetics</i> , <b>2006</b> , 78, 804-814	11	396
201	The Montgomery Asberg and the Hamilton ratings of depression: a comparison of measures. <i>European Neuropsychopharmacology</i> , <b>2006</b> , 16, 601-11	1.2	150
200	Use of bupropion in combination with serotonin reuptake inhibitors. <i>Biological Psychiatry</i> , <b>2006</b> , 59, 203-10	7.9	111
199	An evaluation of the quick inventory of depressive symptomatology and the hamilton rating scale for depression: a sequenced treatment alternatives to relieve depression trial report. <i>Biological Psychiatry</i> , <b>2006</b> , 59, 493-501	7.9	300
198	Algorithms and collaborative-care systems for depression: are they effective and why? A systematic review. <i>Biological Psychiatry</i> , <b>2006</b> , 59, 1029-38	7.9	102
197	An empirical evaluation of the Arizona sexual experience scale and a simple one-item screening test for assessing antipsychotic-related sexual dysfunction in outpatients with schizophrenia and schizoaffective disorder. <i>Schizophrenia Research</i> , <b>2006</b> , 81, 311-6	3.6	49
196	Sexual dysfunction associated with second-generation antipsychotics in outpatients with schizophrenia or schizoaffective disorder: an empirical evaluation of olanzapine, risperidone, and quetiapine. <i>Schizophrenia Research</i> , <b>2006</b> , 86, 244-50	3.6	42
195	Enrolling research subjects from clinical practice: ethical and procedural issues in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial. <i>Psychiatry Research</i> , <b>2006</b> , 141, 193-200	9.9	15
194	Effect of two prednisone exposures on mood and declarative memory. <i>Neurobiology of Learning and Memory</i> , <b>2006</b> , 86, 28-34	3.1	24
193	Self-rated global measure of the frequency, intensity, and burden of side effects. <i>Journal of Psychiatric Practice</i> , <b>2006</b> , 12, 71-9	1.3	176
192	Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. <i>American Journal of Psychiatry</i> , <b>2006</b> , 163, 1531-41; quiz 1666	11.9	244
191	What clinical and symptom features and comorbid disorders characterize outpatients with anxious major depressive disorder: a replication and extension. <i>Canadian Journal of Psychiatry</i> , <b>2006</b> , 51, 823-35	4.8	115
190	Dr. Trivedi and Colleagues Reply. <i>American Journal of Psychiatry</i> , <b>2006</b> , 163, 1293-1294	11.9	4

189	Comparison of self-report and clinician ratings on two inventories of depressive symptomatology. <i>Psychiatric Services</i> , <b>2006</b> , 57, 829-37	3.3	85
188	Substance use disorder comorbidity in major depressive disorder: a confirmatory analysis of the STAR*D cohort. <i>American Journal on Addictions</i> , <b>2006</b> , 15, 278-85	3.7	70
187	A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. <i>American Journal of Psychiatry</i> , <b>2006</b> , 163, 1161-72	11.9	100
186	Item Response Analysis of the Inventory of Depressive Symptomatology. <i>Neuropsychiatric Disease and Treatment</i> , <b>2006</b> , 2, 557-564	3.1	12
185	Children of currently depressed mothers: a STAR*D ancillary study. <i>Journal of Clinical Psychiatry</i> , <b>2006</b> , 67, 126-36	4.6	103
184	Factors associated with health-related quality of life among outpatients with major depressive disorder: a STAR*D report. <i>Journal of Clinical Psychiatry</i> , <b>2006</b> , 67, 185-95	4.6	113
183	Prospective, long-term, multicenter study of the naturalistic outcomes of patients with treatment-resistant depression. <i>Journal of Clinical Psychiatry</i> , <b>2006</b> , 67, 688-95	4.6	144
182	Implementation of the Texas Medication Algorithm Project patient and family education program. <i>Journal of Clinical Psychiatry</i> , <b>2006</b> , 67, 1362-72	4.6	16
181	Age-Related Characteristics of Depression: A Preliminary STAR*D Report. <i>American Journal of Geriatric Psychiatry</i> , <b>2005</b> , 13, 852-860	6.5	42
180	Quality improvement methods as applied to a multicenter effectiveness trial--STAR*D. <i>Contemporary Clinical Trials</i> , <b>2005</b> , 26, 95-112	2.3	6
179	A comparison of electronic monitoring vs. clinician rating of antipsychotic adherence in outpatients with schizophrenia. <i>Psychiatry Research</i> , <b>2005</b> , 133, 129-33	9.9	145
178	Brief psychiatric rating scale expanded version: How do new items affect factor structure?. <i>Psychiatry Research</i> , <b>2005</b> , 135, 217-28	9.9	78
177	A randomized trial of citalopram versus placebo in outpatients with asthma and major depressive disorder: a proof of concept study. <i>Biological Psychiatry</i> , <b>2005</b> , 58, 865-70	7.9	72
176	Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: a naturalistic study. <i>Biological Psychiatry</i> , <b>2005</b> , 58, 355-63	7.9	288
175	Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. <i>Biological Psychiatry</i> , <b>2005</b> , 58, 347-54	7.9	439
174	A one-year comparison of vagus nerve stimulation with treatment as usual for treatment-resistant depression. <i>Biological Psychiatry</i> , <b>2005</b> , 58, 364-73	7.9	264
173	Dr. Scheffer and Colleagues Reply. <i>American Journal of Psychiatry</i> , <b>2005</b> , 162, 2197-a-2198	11.9	
172	Differential Responses to Psychotherapy Versus Pharmacotherapy in Patients With Chronic Forms of Major Depression and Childhood Trauma. <i>Focus (American Psychiatric Publishing)</i> , <b>2005</b> , 3, 131-135	1.1	3

171	Does provider adherence to a treatment guideline change clinical outcomes for patients with bipolar disorder? Results from the Texas Medication Algorithm Project. <i>Psychological Medicine</i> , <b>2005</b> , 35, 1695-706	6.9	37
170	Gender differences in depression: findings from the STAR*D study. <i>Journal of Affective Disorders</i> , <b>2005</b> , 87, 141-50	6.6	292
169	Comorbid psychiatric disorders in depressed outpatients: demographic and clinical features. <i>Journal of Affective Disorders</i> , <b>2005</b> , 87, 43-55	6.6	185
168	A direct comparison of presenting characteristics of depressed outpatients from primary vs. specialty care settings: preliminary findings from the STAR*D clinical trial. <i>General Hospital Psychiatry</i> , <b>2005</b> , 27, 87-96	5.6	56
167	Assessing insomnia severity in depression: comparison of depression rating scales and sleep diaries. <i>Journal of Psychiatric Research</i> , <b>2005</b> , 39, 481-8	5.2	60
166	Escitalopram in clinical practice: results of an open-label trial in a naturalistic setting. <i>Depression and Anxiety</i> , <b>2005</b> , 21, 26-32	8.4	31
165	The Therapeutic Alliance and CBASP-Specific Skill Acquisition in the Treatment of Chronic Depression. <i>Cognitive Therapy and Research</i> , <b>2005</b> , 29, 803-817	2.7	9
164	Self-reported depressive symptom measures: sensitivity to detecting change in a randomized, controlled trial of chronically depressed, nonpsychotic outpatients. <i>Neuropsychopharmacology</i> , <b>2005</b> , 30, 405-16	8.7	96
163	Does pretreatment insomnia or anxiety predict acute response to bupropion SR?. <i>Annals of Clinical Psychiatry</i> , <b>2005</b> , 17, 1-9	1.4	7
162	High frequency EEG activity during sleep: characteristics in schizophrenia and depression. <i>Clinical EEG and Neuroscience</i> , <b>2005</b> , 36, 25-35	2.3	55
161	Psychiatric emergency service use after implementation of managed care in a public mental health system. <i>Psychiatric Services</i> , <b>2005</b> , 56, 691-8	3.3	13
160	Characteristics of insured and noninsured outpatients with depression in STAR(*)D. <i>Psychiatric Services</i> , <b>2005</b> , 56, 995-1004	3.3	25
159	Relief of expressed suicidal intent by ECT: a consortium for research in ECT study. <i>American Journal of Psychiatry</i> , <b>2005</b> , 162, 977-82	11.9	187
158	Effect of structured interviews on evaluation time in pediatric community mental health settings. <i>Psychiatric Services</i> , <b>2005</b> , 56, 1098-103	3.3	13
157	Randomized, placebo-controlled trial of mixed amphetamine salts for symptoms of comorbid ADHD in pediatric bipolar disorder after mood stabilization with divalproex sodium. <i>American Journal of Psychiatry</i> , <b>2005</b> , 162, 58-64	11.9	198
156	Chronic depression: medication (nefazodone) or psychotherapy (CBASP) is effective when the other is not. <i>Archives of General Psychiatry</i> , <b>2005</b> , 62, 513-20		110
155	Age-related characteristics of depression: a preliminary STAR*D report. <i>American Journal of Geriatric Psychiatry</i> , <b>2005</b> , 13, 852-60	6.5	25
154	What moderator characteristics are associated with better prognosis for depression?. <i>Neuropsychiatric Disease and Treatment</i> , <b>2005</b> , 1, 51-7	3.1	30

153	Prevalence and Clinical Correlates of Irritability in Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , <b>2005</b> , 66, 159-166	4.6	53
152	Psychotherapy and medication in the treatment of adult and geriatric depression: which monotherapy or combined treatment?. <i>Journal of Clinical Psychiatry</i> , <b>2005</b> , 66, 455-68	4.6	176
151	A trial of compliance therapy in outpatients with schizophrenia or schizoaffective disorder. <i>Journal of Clinical Psychiatry</i> , <b>2005</b> , 66, 997-1001	4.6	50
150	Clinical and demographic features of atypical depression in outpatients with major depressive disorder: preliminary findings from STAR*D. <i>Journal of Clinical Psychiatry</i> , <b>2005</b> , 66, 1002-11	4.6	133
149	Two-year outcome of vagus nerve stimulation (VNS) for treatment of major depressive episodes. <i>Journal of Clinical Psychiatry</i> , <b>2005</b> , 66, 1097-104	4.6	258
148	15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL. <i>Primary Care Companion To the Journal of Clinical Psychiatry</i> , <b>2005</b> , 7, 106-13		180
147	Prevalence and clinical correlates of irritability in major depressive disorder: a preliminary report from the Sequenced Treatment Alternatives to Relieve Depression study. <i>Journal of Clinical Psychiatry</i> , <b>2005</b> , 66, 159-66; quiz 147, 273-4	4.6	20
146	Clinical results for patients with major depressive disorder in the Texas Medication Algorithm Project. <i>Archives of General Psychiatry</i> , <b>2004</b> , 61, 669-80		225
145	Web-based communications and management of a multi-center clinical trial: the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) project. <i>Clinical Trials</i> , <b>2004</b> , 1, 387-98	2.2	38
144	Methods of testing feasibility for sequenced treatment alternatives to relieve depression (STAR*D). <i>Journal of Psychiatric Research</i> , <b>2004</b> , 38, 241-8	5.2	6
143	Development of a computerized assessment of clinician adherence to a treatment guideline for patients with bipolar disorder. <i>Journal of Psychiatric Research</i> , <b>2004</b> , 38, 285-94	5.2	4
142	Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. <i>Contemporary Clinical Trials</i> , <b>2004</b> , 25, 119-42		725
141	Acupuncture: a promising treatment for depression during pregnancy. <i>Journal of Affective Disorders</i> , <b>2004</b> , 83, 89-95	6.6	145
140	Clinical features of depressed outpatients with and without co-occurring general medical conditions in STAR*D. <i>General Hospital Psychiatry</i> , <b>2004</b> , 26, 421-9	5.6	83
139	The Implementation of Cognitive Therapy in STAR*D. <i>Cognitive Therapy and Research</i> , <b>2004</b> , 28, 819-833	2.7	5
138	An open-label trial of quetiapine for antipsychotic-induced sexual dysfunction. <i>Journal of Sex and Marital Therapy</i> , <b>2004</b> , 30, 325-32	2.7	32
137	Hippocampal volume, spectroscopy, cognition, and mood in patients receiving corticosteroid therapy. <i>Biological Psychiatry</i> , <b>2004</b> , 55, 538-45	7.9	203
136	One-year clinical outcomes of depressed public sector outpatients: a benchmark for subsequent studies. <i>Biological Psychiatry</i> , <b>2004</b> , 56, 46-53	7.9	77



135	Factors that differentiate early vs. later onset of major depression disorder. <i>Psychiatry Research</i> , <b>2004</b> , 129, 127-40	9.9	103
134	Development of the Brief Bipolar Disorder Symptom Scale for patients with bipolar disorder. <i>Psychiatry Research</i> , <b>2004</b> , 127, 137-45	9.9	17
133	Randomized, placebo-controlled trial of fluoxetine for acute treatment of minor depressive disorder. <i>American Journal of Psychiatry</i> , <b>2004</b> , 161, 1864-71	11.9	63
132	The Texas medication algorithm project: clinical results for schizophrenia. <i>Schizophrenia Bulletin</i> , <b>2004</b> , 30, 627-47	1.3	69
131	Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*D. <i>Psychological Medicine</i> , <b>2004</b> , 34, 1299-308	6.9	261
130	Cognitive-behavioral analysis system of psychotherapy as a maintenance treatment for chronic depression. <i>Journal of Consulting and Clinical Psychology</i> , <b>2004</b> , 72, 681-8	6.5	91
129	Therapist Variables That Predict Symptom Change in Psychotherapy With Chronically Depressed Outpatients.. <i>Psychotherapy</i> , <b>2004</b> , 41, 255-265	2.5	35
128	The cost consequences of treatment-resistant depression. <i>Journal of Clinical Psychiatry</i> , <b>2004</b> , 65, 341-7	4.6	86
127	Speed of response and remission in major depressive disorder with acute electroconvulsive therapy (ECT): a Consortium for Research in ECT (CORE) report. <i>Journal of Clinical Psychiatry</i> , <b>2004</b> , 65, 485-91	4.6	263
126	The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. <i>Journal of Clinical Psychiatry</i> , <b>2004</b> , 65, 500-8	4.6	125
125	Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2003</b> , 100, 14293-6	11.5	584
124	A quality improvement process for implementing the Texas algorithm for schizophrenia in Ohio. <i>Psychiatric Services</i> , <b>2003</b> , 54, 1646-9	3.3	6
123	Vagus nerve stimulation (VNS): utility in neuropsychiatric disorders. <i>International Journal of Neuropsychopharmacology</i> , <b>2003</b> , 6, 73-83	5.8	47
122	Therapeutic reactance as a predictor of outcome in the treatment of chronic depression. <i>Journal of Consulting and Clinical Psychology</i> , <b>2003</b> , 71, 1025-35	6.5	18
121	Impact of structured clinical interviews on physicians' practices in community mental health settings. <i>Psychiatric Services</i> , <b>2003</b> , 54, 712-8	3.3	39
120	The effects of psychotherapy, nefazodone, and their combination on subjective assessment of disturbed sleep in chronic depression. <i>Sleep</i> , <b>2003</b> , 26, 130-6	1.1	83
119	Catching up on health outcomes: the Texas Medication Algorithm Project. <i>Health Services Research</i> , <b>2003</b> , 38, 311-31	3.4	26
118	Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. <i>Psychiatric Clinics of North America</i> , <b>2003</b> , 26, 457-94, x	3.1	373

117	The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. <i>Biological Psychiatry</i> , <b>2003</b> , 54, 573-83	7.9	2278
116	Randomized, placebo-controlled trial of nefazodone maintenance treatment in preventing recurrence in chronic depression. <i>Biological Psychiatry</i> , <b>2003</b> , 54, 806-17	7.9	59
115	The effects of vagus nerve stimulation on sleep EEG in depression: a preliminary report. <i>Journal of Psychosomatic Research</i> , <b>2003</b> , 54, 475-82	4.1	30
114	Psychosis in bipolar disorder: phenomenology and impact on morbidity and course of illness. <i>Comprehensive Psychiatry</i> , <b>2003</b> , 44, 263-9	7.3	147
113	Research issues in the study of difficult-to-treat depression. <i>Biological Psychiatry</i> , <b>2003</b> , 53, 743-53	7.9	136
112	Clinician ratings vs. global ratings of symptom severity: a comparison of symptom measures in the bipolar disorder module, phase II, Texas Medication Algorithm Project. <i>Psychiatry Research</i> , <b>2003</b> , 117, 167-75	9.9	5
111	The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). <i>JAMA - Journal of the American Medical Association</i> , <b>2003</b> , 289, 3095-105	27.4	5502
110	Depression, IV: STAR*D treatment trial for depression. <i>American Journal of Psychiatry</i> , <b>2003</b> , 160, 237	11.9	85
109	Texas Medication Algorithm Project, phase 3 (TMAP-3): rationale and study design. <i>Journal of Clinical Psychiatry</i> , <b>2003</b> , 64, 357-69	4.6	74
108	Texas Medication Algorithm Project, phase 3 (TMAP-3): clinical results for patients with a history of mania. <i>Journal of Clinical Psychiatry</i> , <b>2003</b> , 64, 370-82	4.6	69
107	Continuation treatment of chronic depression: a comparison of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination. <i>Psychopharmacology Bulletin</i> , <b>2003</b> , 37, 73-87	0.9	24
106	Implementing practice guidelines for depression: applying a new framework to an old problem. <i>General Hospital Psychiatry</i> , <b>2002</b> , 24, 35-42	5.6	62
105	Enhancing the technology of clinical trials and the trials model to evaluate newly developed, targeted antidepressants. <i>Neuropsychopharmacology</i> , <b>2002</b> , 27, 319-28	8.7	19
104	Itemized clinician ratings versus global ratings of symptom severity in patients with schizophrenia. <i>International Journal of Methods in Psychiatric Research</i> , <b>2002</b> , 11, 45-53	4.3	2
103	Naturalistic study of the early psychiatric use of citalopram in the United States. <i>Depression and Anxiety</i> , <b>2002</b> , 16, 121-7	8.4	6
102	Tiagabine in treatment refractory bipolar disorder: a clinical case series. <i>Bipolar Disorders</i> , <b>2002</b> , 4, 283-93	3.8	49
101	Pretreatment Correlates of the Therapeutic Alliance in the Chronically Depressed. <i>Journal of Contemporary Psychotherapy</i> , <b>2002</b> , 32, 281-290	2.3	6
100	Practice guidelines in mental health and addiction services: contributions from the American College of Mental Health Administration. <i>Administration and Policy in Mental Health and Mental Health Services Research</i> , <b>2002</b> , 30, 21-33	3.1	5

99	A descriptive analysis of minor depression. <i>American Journal of Psychiatry</i> , <b>2002</b> , 159, 637-43	11.9	130
98	Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression. <i>Archives of General Psychiatry</i> , <b>2002</b> , 59, 233-9		97
97	Early physical and sexual abuse associated with an adverse course of bipolar illness. <i>Biological Psychiatry</i> , <b>2002</b> , 51, 288-97	7.9	300
96	Does psychosocial functioning improve independent of depressive symptoms? A comparison of nefazodone, psychotherapy, and their combination. <i>Biological Psychiatry</i> , <b>2002</b> , 51, 123-33	7.9	172
95	Vagus nerve stimulation (VNS) for major depressive episodes: one year outcomes. <i>Biological Psychiatry</i> , <b>2002</b> , 51, 280-7	7.9	224
94	Skating to where the puck is going to be: a plan for clinical trials and translation research in mood disorders. <i>Biological Psychiatry</i> , <b>2002</b> , 52, 631-54	7.9	13
93	Symptomatic and syndromal anxiety in chronic forms of major depression: effect of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination. <i>Journal of Clinical Psychiatry</i> , <b>2002</b> , 63, 434-41	4.6	22
92	Differential effects of nefazodone and cognitive behavioral analysis system of psychotherapy on insomnia associated with chronic forms of major depression. <i>Journal of Clinical Psychiatry</i> , <b>2002</b> , 63, 493-500	4.6	34
91	The impact of treatment-resistant depression on health care utilization and costs. <i>Journal of Clinical Psychiatry</i> , <b>2002</b> , 63, 963-71	4.6	246
90	Psychotherapies for Depressive Disorders: A Review <b>2001</b> , 161-232		10
89	Ketoconazole in bipolar patients with depressive symptoms: a case series and literature review. <i>Bipolar Disorders</i> , <b>2001</b> , 3, 23-9	3.8	36
88	Rate of switch in bipolar patients prospectively treated with second-generation antidepressants as augmentation to mood stabilizers. <i>Bipolar Disorders</i> , <b>2001</b> , 3, 259-265	3.8	92
87	Response in relation to baseline anxiety levels in major depressive disorder treated with bupropion sustained release or sertraline. <i>Neuropsychopharmacology</i> , <b>2001</b> , 25, 131-8	8.7	33
86	Vagus nerve stimulation (VNS) for treatment-resistant depression: efficacy, side effects, and predictors of outcome. <i>Neuropsychopharmacology</i> , <b>2001</b> , 25, 713-28	8.7	358
85	The Stanley Foundation Bipolar Network. I. Rationale and methods. <i>British Journal of Psychiatry</i> , <b>2001</b> , 41, s169-76	5.4	67
84	The Stanley Foundation Bipolar Network: 2. Preliminary summary of demographics, course of illness and response to novel treatments. <i>British Journal of Psychiatry</i> , <b>2001</b> , 178, s177-s183	5.4	31
83	Onset and persistence of postpartum depression in an inner-city maternal health clinic system. <i>American Journal of Psychiatry</i> , <b>2001</b> , 158, 1856-63	11.9	272
82	Axis I psychiatric comorbidity and its relationship to historical illness variables in 288 patients with bipolar disorder. <i>American Journal of Psychiatry</i> , <b>2001</b> , 158, 420-6	11.9	528

81	Implementing evidence-based practices for persons with severe mental illnesses. <i>Psychiatric Services</i> , <b>2001</b> , 52, 45-50	3.3	338
80	Validation of the Inventory of Depressive Symptomatology (IDS) in Cocaine Dependent Inmates. <i>Journal of Offender Rehabilitation</i> , <b>2001</b> , 32, 15-30	0.9	5
79	The Influence of Age on the Response of Major Depression to Electroconvulsive Therapy: A C.O.R.E. Report. <i>American Journal of Geriatric Psychiatry</i> , <b>2001</b> , 9, 382-390	6.5	145
78	ECT remission rates in psychotic versus nonpsychotic depressed patients: a report from CORE. <i>Journal of ECT</i> , <b>2001</b> , 17, 244-53	2	291
77	Sleep polysomnography as a predictor of recurrence in children and adolescents with major depressive disorder. <i>International Journal of Neuropsychopharmacology</i> , <b>2001</b> , 4, 159-68	5.8	62
76	Which depressed patients respond to nefazodone and when?. <i>Journal of Clinical Psychiatry</i> , <b>2001</b> , 62, 158-63	4.6	22
75	Texas Medication Algorithm Project. <i>Journal of Clinical Psychiatry</i> , <b>2001</b> , 62, 439-447	4.6	40
74	Do bupropion SR and sertraline differ in their effects on anxiety in depressed patients?. <i>Journal of Clinical Psychiatry</i> , <b>2001</b> , 62, 776-81	4.6	37
73	Methods to improve diagnostic accuracy in a community mental health setting. <i>American Journal of Psychiatry</i> , <b>2000</b> , 157, 1599-605	11.9	290
72	Depression and chronic low back pain: establishing priorities in treatment. <i>Spine</i> , <b>2000</b> , 25, 2566-71	3.3	96
71	The Inventory of Depressive Symptomatology (IDS): Clinician (IDS-C) and Self-Report (IDS-SR) ratings of depressive symptoms. <i>International Journal of Methods in Psychiatric Research</i> , <b>2000</b> , 9, 45-59	4.3	251
70	Temporal Characteristics of Delta Activity During NREM Sleep in Depressed Outpatients and Healthy Adults: Group and Sex Effects. <i>Sleep</i> , <b>2000</b> , 23, 1-11	1.1	60
69	Structured interview and uniform assessment improves diagnostic reliability. <i>Journal of Child and Adolescent Psychopharmacology</i> , <b>2000</b> , 10, 119-31	2.9	13
68	A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. <i>New England Journal of Medicine</i> , <b>2000</b> , 342, 1462-70	50.2	985
67	Effect size of lithium, divalproex sodium, and carbamazepine in children and adolescents with bipolar disorder. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , <b>2000</b> , 39, 713-20	7.2	281
66	Vagus nerve stimulation. A potential therapy for resistant depression?. <i>Psychiatric Clinics of North America</i> , <b>2000</b> , 23, 757-83	3.1	61
65	The Texas Medication Algorithm Project Patient and Family Education Program: a consumer-guided initiative. <i>Journal of Clinical Psychiatry</i> , <b>2000</b> , 61, 477-86	4.6	18
64	Depression in Asthma: Prevalence and Clinical Implications. <i>Primary Care Companion To the Journal of Clinical Psychiatry</i> , <b>2000</b> , 2, 153-158		46

63	Platelet alpha2-adrenergic receptor coupling efficiency to Gi protein in subjects with post-traumatic stress disorder and normal controls. <i>Psychopharmacology</i> , <b>1999</b> , 141, 258-66	4.7	12
62	Neutrophil beta2-adrenergic receptor coupling efficiency to Gs protein in subjects with post-traumatic stress disorder and normal controls. <i>Psychopharmacology</i> , <b>1999</b> , 143, 131-40	4.7	10
61	Effects of fluoxetine on the polysomnogram in outpatients with major depression. <i>Neuropsychopharmacology</i> , <b>1999</b> , 20, 447-59	8.7	45
60	Hippocampal remodeling and damage by corticosteroids: implications for mood disorders. <i>Neuropsychopharmacology</i> , <b>1999</b> , 21, 474-84	8.7	243
59	Measuring costs of guideline-driven mental health care: the Texas Medication Algorithm Project. <i>Journal of Mental Health Policy and Economics</i> , <b>1999</b> , 2, 111-121	1.3	19
58	The Texas Children's Medication Algorithm Project: report of the Texas Consensus Conference Panel on Medication Treatment of Childhood Major Depressive Disorder. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , <b>1999</b> , 38, 1442-54	7.2	102
57	Strategies for Implementing Psychiatric Medication Algorithms in the Public Sector. <i>Journal of Psychiatric Practice</i> , <b>1999</b> , 5, 32-36	1.3	6
56	Implementing Guidelines and Systems of Care. <i>Journal of Psychiatric Practice</i> , <b>1999</b> , 5, 75-86	1.3	19
55	The Texas Medication Algorithm Project: development and implementation of the schizophrenia algorithm. <i>Psychiatric Services</i> , <b>1999</b> , 50, 69-74	3.3	38
54	The Texas Medication Algorithm Project. <i>Journal of Clinical Psychiatry</i> , <b>1999</b> , 60, 142-156	4.6	160
53	Medication treatment for the severely and persistently mentally ill: the Texas Medication Algorithm Project. <i>Journal of Clinical Psychiatry</i> , <b>1999</b> , 60, 284-91	4.6	65
52	The Texas Medication Algorithm Project (TMAP) schizophrenia algorithms. <i>Journal of Clinical Psychiatry</i> , <b>1999</b> , 60, 649-57	4.6	78
51	Fluoxetine in child and adolescent depression: acute and maintenance treatment. <i>Depression and Anxiety</i> , <b>1998</b> , 7, 32-9	8.4	128
50	Treating major depression in primary care practice: an update of the Agency for Health Care Policy and Research Practice Guidelines. <i>Archives of General Psychiatry</i> , <b>1998</b> , 55, 1121-7		262
49	Is there a role for continuation phase cognitive therapy for depressed outpatients?. <i>Journal of Consulting and Clinical Psychology</i> , <b>1998</b> , 66, 1036-1040	6.5	47
48	Texas Medication Algorithm Project. <i>Journal of Clinical Psychiatry</i> , <b>1998</b> , 59, 345-351	4.6	70
47	The Treatment of Chronic Depression, Part 1. <i>Journal of Clinical Psychiatry</i> , <b>1998</b> , 59, 589-597	4.6	40
46	The treatment of chronic depression, part 2: a double-blind, randomized trial of sertraline and imipramine. <i>Journal of Clinical Psychiatry</i> , <b>1998</b> , 59, 598-607	4.6	97

45	The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine. <i>Journal of Clinical Psychiatry</i> , <b>1998</b> , 59, 608-19	4.6	213
44	Recurrence of major depressive disorder in hospitalized children and adolescents. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , <b>1997</b> , 36, 785-92	7.2	96
43	Dexamethasone response, thyrotropin-releasing hormone stimulation, rapid eye movement latency, and subtypes of depression. <i>Biological Psychiatry</i> , <b>1997</b> , 41, 915-28	7.9	58
42	Relationship between objective and subjective sleep measures in depressed patients and healthy controls. <i>Depression and Anxiety</i> , <b>1997</b> , 5, 97-102	8.4	114
41	Desipramine versus phenelzine in recurrent unipolar depression: clinical characteristics and treatment response. <i>Journal of Clinical Psychopharmacology</i> , <b>1997</b> , 17, 78-83	1.7	6
40	A multicenter, double-blind comparison of the effects of nefazodone and fluoxetine on sleep architecture and quality of sleep in depressed outpatients. <i>Journal of Clinical Psychopharmacology</i> , <b>1997</b> , 17, 161-8	1.7	66
39	Plasma GABA predicts acute response to divalproex in mania. <i>Biological Psychiatry</i> , <b>1996</b> , 39, 278-84	7.9	40
38	National Institute of Mental Health Workshop Report on the Treatment of Bipolar Disorder. <i>Biological Psychiatry</i> , <b>1996</b> , 40, 215-20	7.9	34
37	Impulsivity and neuroendocrine response to buspirone in bulimia nervosa. <i>Biological Psychiatry</i> , <b>1996</b> , 39, 371-4	7.9	17
36	The dexamethasone suppression test in patients with mood disorders. <i>Journal of Clinical Psychiatry</i> , <b>1996</b> , 57, 470-84	4.6	125
35	MAOIs in the contemporary treatment of depression. <i>Neuropsychopharmacology</i> , <b>1995</b> , 12, 185-219	8.7	149
34	Stability of plasma GABA at four-year follow-up in patients with primary unipolar depression. <i>Biological Psychiatry</i> , <b>1995</b> , 37, 806-10	7.9	36
33	Benzodiazepines as antidepressants: does GABA play a role in depression?. <i>Biological Psychiatry</i> , <b>1995</b> , 38, 578-91	7.9	113
32	Dream recall and major depression: A preliminary report.. <i>Dreaming</i> , <b>1995</b> , 5, 189-198	6	127
31	Compliance With Pharmacotherapy in Mood Disorders. <i>Psychiatric Annals</i> , <b>1995</b> , 25, 269-279	0.5	32
30	Treating Depression to Remission. <i>Psychiatric Annals</i> , <b>1995</b> , 25, 704-709	0.5	51
29	The effects of nefazodone on sleep architecture in depression. <i>Neuropsychopharmacology</i> , <b>1994</b> , 10, 123-7	8.7	83
28	The effects of fluoxetine on the polysomnogram of depressed outpatients: a pilot study. <i>Neuropsychopharmacology</i> , <b>1994</b> , 10, 85-91	8.7	55



27	Efficacy, safety, and indications for tricyclic and newer antidepressants. <i>Depression</i> , <b>1994</b> , 2, 127-137		16
26	Tricyclics and newer antidepressant medications: Treatment options for treatment-resistant depressions. <i>Depression</i> , <b>1994</b> , 2, 152-168		15
25	Polysomnogram in major depressive and obsessive-compulsive disorders: A preliminary study. <i>Depression</i> , <b>1994</b> , 2, 297-302		4
24	Latency to rapid eye movement sleep as a predictor of treatment response to fluoxetine and placebo in nonpsychotic depressed outpatients. <i>Psychiatry Research</i> , <b>1994</b> , 52, 327-39	9.9	27
23	Short-term psychotherapy of depressive disorders: current status and future directions. <i>Psychiatry (New York)</i> , <b>1994</b> , 57, 115-32	1	65
22	Tridimensional Personality Questionnaire and serotonin in bulimia nervosa. <i>Psychiatry Research</i> , <b>1993</b> , 48, 9-15	9.9	56
21	Low plasma GABA is a trait-like marker for bipolar illness. <i>Neuropsychopharmacology</i> , <b>1993</b> , 9, 125-32	8.7	90
20	Clinical practice guidelines. Good news, bad news, or no news?. <i>Archives of General Psychiatry</i> , <b>1993</b> , 50, 483-90		56
19	Low plasma gamma-aminobutyric acid levels in male patients with depression. <i>Biological Psychiatry</i> , <b>1992</b> , 32, 354-63	7.9	85
18	Depressive symptoms by self-report in adolescence: phase I of the development of a questionnaire for depression by self-report. <i>Journal of Child Neurology</i> , <b>1990</b> , 5, 114-21	2.5	53
17	Age-adjusted threshold values for reduced REM latency in unipolar depression using ROC analysis. <i>Biological Psychiatry</i> , <b>1990</b> , 27, 841-53	7.9	23
16	Secular trend in unipolar depression: a hypothesis. <i>Journal of Affective Disorders</i> , <b>1989</b> , 16, 71-5	6.6	15
15	Depression and dexamethasone suppression testing in children and adolescents. <i>Journal of Child Neurology</i> , <b>1987</b> , 2, 31-7	2.5	26
14	Polysomnographic findings in recently drug-free and clinically remitted depressed patients. <i>Archives of General Psychiatry</i> , <b>1986</b> , 43, 878-84		164
13	Do thinking patterns predict depressive symptoms?. <i>Cognitive Therapy and Research</i> , <b>1986</b> , 10, 225-235	2.7	69
12	The Inventory for Depressive Symptomatology (IDS): preliminary findings. <i>Psychiatry Research</i> , <b>1986</b> , 18, 65-87	9.9	617
11	Alprazolam vs amitriptyline in depressions with reduced REM latencies. <i>Archives of General Psychiatry</i> , <b>1985</b> , 42, 1154-9		44
10	Cognitive patterns in symptomatic and remitted unipolar major depression.. <i>Journal of Abnormal Psychology</i> , <b>1984</b> , 93, 31-40	7	243

9	Cognitive Therapy of Depression: Rationale, Techniques, and Efficacy. <i>Psychiatric Clinics of North America</i> , <b>1983</b> , 6, 105-127	3.1	16
8	Group versus individual cognitive therapy: A pilot study. <i>Cognitive Therapy and Research</i> , <b>1981</b> , 5, 95-103	2.7	72
7	Psychotherapy of the affective psychoses. <i>American Journal of Psychoanalysis</i> , <b>1980</b> , 40, 99-121	0.4	5
6	A pilot study of the treatment of outpatients with chronic pain: symptom control, stimulus control and social system intervention. <i>Pain</i> , <b>1978</b> , 5, 163-172	8	42
5	Cognitive therapy of depression and suicide. <i>American Journal of Psychotherapy</i> , <b>1978</b> , 32, 201-19	1.3	37
4	Genomics-based identification of a potential causal role for acylcarnitine metabolism in depression		2
3	Outcome measures of depression.		10
2	Alterations in Acylcarnitines, Amines, and Lipids Inform about Mechanism of Action of Citalopram/Escitalopram in Major Depression		2
1	Acylcarnitine Metabolomic Profiles Inform Clinically-Defined Major Depressive Phenotypes		1